JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor, a highly expressed tumor-selective protein in prostate cancer cells Among patients with measurable disease in the 50 mg cohort, 75% achieved a complete or partial tumor response in the Phase 1 study 77% of patients achieved a confirmed PSA reduction of at least 50%, including nearly half whose PSA levels fell by at least 90%
